SCHEMBL4166844

SCHEMBL4166844

CCOC(=O)c1[nH]c2c(Br)cccc2c1CCCOc1cc(C)cc(C)c1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARK3 P27448 2/20 0.62
NEK4 P51957 2/20 0.62
PRKCD Q05655 2/20 0.62
MAP4K2 Q12851 2/20 0.62
CAMK2B Q13554 2/20 0.62
CAMK2G Q13555 2/20 0.62
CAMK2D Q13557 2/20 0.62
MARK2 Q7KZI7 2/20 0.62
TAOK1 Q7L7X3 2/20 0.62
PIM3 Q86V86 2/20 0.62
MINK1 Q8N4C8 2/20 0.62
HIPK4 Q8NE63 2/20 0.62
AURKB Q96GD4 2/20 0.62
HIPK2 Q9H2X6 2/20 0.62
MAP3K20 Q9NYL2 2/20 0.62
MAP4K5 Q9Y4K4 2/20 0.62
CDC7 O00311 1/20 0.62
AXL P30530 1/20 0.62
FRK P42685 1/20 0.62
BLK P51451 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4170647 0.89 MCL1 (0.49) MARK3NEK4PRKCDMAP4K2CAMK2B
SCHEMBL4162321 0.89 MCL1 (0.49) MARK3NEK4PRKCDMAP4K2CAMK2B
SCHEMBL4164110 0.89 MCL1 (0.50) MARK3NEK4PRKCDMAP4K2CAMK2B
SCHEMBL4170079 0.86 MCL1 (0.56) MARK3NEK4PRKCDMAP4K2CAMK2B
SCHEMBL4165286 0.83 MCL1 (0.60) MARK3NEK4PRKCDCAMK2BCAMK2G
SCHEMBL4158786 0.83 MCL1 (0.49) MARK3NEK4PRKCDMAP4K2CAMK2B
SCHEMBL4166001 0.83 MCL1 (0.53) MARK3NEK4PRKCDMAP4K2CAMK2B
SCHEMBL4168089 0.82 MCL1 (0.57) MCL1HTR6HTR1ADRD2DRD4
SCHEMBL4165824 0.82 NEK4 (0.60) MARK3NEK4PRKCDMAP4K2CAMK2B
SCHEMBL15622097 0.82 MCL1 (0.71) MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3243814-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2018-10-17 EP disclosed
EP-3243814-A1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS AbbVie Inc. (US) 2017-11-15 EP disclosed
EP-2134684-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2017-08-02 EP disclosed
US-9359296-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2016-06-07 US disclosed
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC (US) 2015-10-08 US disclosed
US-9035047-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2015-05-19 US disclosed
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC. (US) 2014-02-20 US disclosed
US-8445679-B2 7-substituted indole MCL-1 inhibitors ABBVIE INC. (US) 2013-05-21 US disclosed
EP-2134684-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS Abbott Laboratories (US) 2009-12-23 EP disclosed
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-02-26 US disclosed
WO-2008131000-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MARK3 2332/4885NEK4 1438/4885PRKCD 2091/4885
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MARK3 2332/4885NEK4 1438/4885PRKCD 2091/4885
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MARK3 2332/4885NEK4 1438/4885PRKCD 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.